Immunocellular Therapeutics, Ltd.
Records under this name other than the patents Immunocellular Therapeutics, Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 3 patents it holds.
Showing 1 to 10 of 10 · Back to Immunocellular Therapeutics, Ltd.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,096,996 | Cancer vaccines and vaccination methods Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 7,687,607 | Monoclonal Antibodies and Cell Surface Antigens for the Detection and Treatment of Small Cell Lung Cancer (SCLC) Term ended Term ended Nov 1, 2021 · High confidence | Term ended | Term ended Nov 1, 2021 | High confidence |
| US 6,376,654 | Myeloma cell and ovarian cancer cell surface glycoproteins, antibodies thereto, and uses thereof Formerly held Term ended Term ended Aug 13, 2019 · From the USPTO record | Term ended | Term ended Aug 13, 2019 | From the USPTO record |
| US 7,226,750 | Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof Formerly held Lapsed on the fee record Ended Jun 5, 2019 · From the USPTO record | Lapsed on the fee record | Ended Jun 5, 2019 | From the USPTO record |
| US 7,183,389 | Monoclonal Antibodies and Cell Surface Antigens for the Detection and Treatment of Small Cell Lung Cancer (SCLC) Lapsed on the fee record Ended Feb 27, 2019 · High confidence | Lapsed on the fee record | Ended Feb 27, 2019 | High confidence |
| US 7,691,376 | Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof Formerly held Lapsed on the fee record Ended Apr 6, 2018 · From the USPTO record | Lapsed on the fee record | Ended Apr 6, 2018 | From the USPTO record |
| US 6,986,891 | Myeloma cell and ovarian cancer cell surface glycoproteins, antibodies thereto, and uses thereof Formerly held Lapsed on the fee record Ended Jan 17, 2018 · From the USPTO record | Lapsed on the fee record | Ended Jan 17, 2018 | From the USPTO record |
| US 7,498,129 | Myeloma cell and ovarian cancer cell surface glycoproteins, antibodies thereto, and uses thereof Formerly held Lapsed on the fee record Ended Mar 3, 2017 · From the USPTO record | Lapsed on the fee record | Ended Mar 3, 2017 | From the USPTO record |
| US 7,435,415 | Monoclonal Antibodies and Cell Surface Antigens for the Detection and Treatment of Small Cell Lung Cancer (SCLC) Lapsed on the fee record Ended Oct 14, 2016 · High confidence | Lapsed on the fee record | Ended Oct 14, 2016 | High confidence |
| US 7,435,554 | Monoclonal Antibodies and Cell Surface Antigens for the Detection and Treatment of Small Cell Lung Cancer (SCLC) Lapsed on the fee record Ended Oct 14, 2016 · High confidence | Lapsed on the fee record | Ended Oct 14, 2016 | High confidence |